Trasylol, or aprotinin, is a blood clotting drug that is used during open heart surgery. Bayer Pharmaceuticals manufactured this drug beginning in 1993. As early as January 2006, studies were released that reported an increase risk of severe adverse reactions, including kidney failure, heart attack, and stroke in patients treated with this product. One medical researcher opined that 22,000 lives could have been saved if Trasylol had been taken off the market when he first published his study in January 2006. In November of 2007, Bayer agreed to temporarily suspend the marketing of Trasylol until further review could be completed.
Please contact an attorney to discuss Trasylol injury by filling out the form on the right hand side of the page.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.